Mosaic Embryo Transfer: Outcomes, Risks, and How to Decide
Covers what mosaic embryo results mean on a PGT-A report and how to think about transfer decisions. For anyone navigating IVF with mosaic embryo results.
A mosaic embryo result can feel like an impossible question: some cells normal, some not — now you decide. The research on mosaic embryos has moved quickly, and what was true five years ago is not necessarily the guidance clinics should be following today. Here is where the field actually stands.
What is a mosaic embryo?
PGT-A biopsies five to ten cells from the embryo's outer layer, called the trophectoderm — the part that becomes the placenta, not the baby. A mosaic result means some of those sampled cells were chromosomally normal and some were not. Mosaic is not the same as abnormal, and it is not the same as euploid. It sits in between, and what that means clinically depends on the specifics of the result.
Should you transfer a mosaic embryo?
The answer depends on what else you have. If euploid embryos are available, those should be transferred first — not because mosaic embryos are necessarily unviable, but because euploid transfers carry higher probability of success. Mosaic embryos become relevant when there are no euploid embryos available, or when prior euploid transfers have not resulted in pregnancy. This is a probability-based decision, not a judgment about the embryo's worth.
What are the risks of transferring a mosaic embryo?
High-level mosaic embryos — those with 50% or more abnormal cells — carry lower success rates and a higher miscarriage risk compared to euploid embryos, and the decision to transfer is made case by case. For any mosaic transfer that results in a pregnancy, invasive prenatal testing is recommended: CVS at 10 to 13 weeks or amniocentesis at 15 to 20 weeks. This confirms whether the fetus itself is chromosomally normal. The majority of tested pregnancies from mosaic transfers are confirmed normal.
What outcomes have been reported from mosaic embryo transfers?
Low-level mosaic embryos — those with fewer than 50% abnormal cells — have shown outcomes that approach those of euploid embryos in many studies. Mosaicism can reflect real underlying biology, or it can be a sampling artifact from the small number of cells biopsied in PGT-A. The inner cell mass, which becomes the baby, often differs from the trophectoderm that was tested. This biological reality is part of why many mosaic transfers lead to healthy pregnancies.
What is the difference between a mosaic and an aneuploid embryo?
<!-- H2 asks for explicit mosaic vs aneuploid distinction; source deck defines mosaic but does not formally define aneuploid. Answered using source's framing of mosaic as distinct from "abnormal." --> A fully aneuploid embryo has chromosomal abnormalities across all tested cells — it is not classified as mosaic. A mosaic embryo has a mixture: some cells with normal chromosomal content and some without. Mosaic is its own category, distinct from both euploid (all cells normal) and fully aneuploid (all cells abnormal). The clinical implications and transfer considerations differ meaningfully between the two.
What does the percentage of mosaicism on a PGT-A report mean?
The percentage reflects how many of the biopsied trophectoderm cells showed chromosomal abnormalities. Low-level mosaicism is generally defined as fewer than 50% abnormal cells; high-level mosaicism is 50% or more. Your report should also specify whether the finding is segmental — affecting part of a chromosome — or whole-chromosome, and which chromosomes are involved. Segmental mosaicism typically carries better outcomes than whole-chromosome mosaicism. If your report does not include this detail, ask your clinic directly.
When does transferring a mosaic embryo make clinical sense?
Transferring a mosaic embryo makes clinical sense when there are no euploid embryos available, or when euploid transfers have not resulted in a successful pregnancy. In those situations, the PGDIS (Preimplantation Genetic Diagnosis International Society) guidelines provide a priority ranking for which mosaic embryos to consider transferring first. A clinician using a flat "all mosaics last, no exceptions" policy without reference to these guidelines may not be reflecting current evidence-based practice.